Register for our free email digests:
Latest From OriGene Technologies Inc.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Tools – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced August-September 2015.
China attracted $1.9 billion in private equity investment in health care-related fields in 2013, making the sector second only to real estate. But investors at a recent forum in Beijing had divergent opinions on whether the smart money should head into developing devices, clinics or new drug R&D.
Roche is optioning Isis’ Huntington’s disease antisense candidates in a deal worth $282 million and Thermo Fisher paid just over $15 billion for Life Technologies. Biopharma financing was up 23% to $1.2 billion, device fundraising down 35% to $338 million.
- Monitoring Equipment & Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Somanetics Corp.
- Senior Management
Bruce J Barrett, Pres. & CEO
William M Iacona, VP, CFO
Arik Anderson, SVP, R&D
Dominic J Spadafore, VP, US Sales & Mktg.
- Contact Info
Phone: (248) 244-1400
2600 Troy Center Dr.
Troy, MI 48083-4208
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.